Studies presented represent key focus areas,
including building evidence for clinical utility of comprehensive
genomic profiling; overcoming market access barriers, and
progressing the whole-genome approach for MRD
SAN
DIEGO, May 29, 2024 /PRNewswire/ -- Illumina Inc.
(NASDAQ: ILMN), a global leader in DNA sequencing and array-based
technologies, today announced some of its latest research being
presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting, May 31–June 4 in Chicago. Highlights include data from several
studies in partnership with Labcorp, a global leader of innovative
and comprehensive laboratory services; research with Sarah Cannon
Research Institute (SCRI) demonstrating further evidence to support
the use of comprehensive genomic profiling (CGP) over single-gene
testing (SGT); and the latest data supporting the development of
Illumina's molecular residual disease (MRD) assay, which is
currently underway in collaboration with major pharma companies. In
total, Illumina had 14 abstracts accepted to the meeting.
"Illumina is proud of our collaborations across all areas of the
oncology, research, clinical, and payer communities to produce
strong evidence to further enable genomic testing for patients with
cancer," said Nicole Berry, head of
the Americas region at Illumina. "Through this continued
commitment, we can support our customers and partners to achieve
their precision oncology goals for the benefit of patients
everywhere."
Illumina and Labcorp: innovation-driven research
Illumina and Labcorp share five abstracts accepted at ASCO. The
organizations have a longstanding partnership working to build
evidence of the clinical impact and value of comprehensive
biomarker testing for patients across different cancer types, to
ultimately increase community oncology physicians' access to the
latest genomic testing. Among the joint abstracts accepted is a
poster presentation on the development and application of a machine
learning algorithm trained on multiomics biomarkers for the
detection of tumor microsatellite instability (MSI), which is
common in certain cancers (Abstract 1554). The study analyzed
samples from 1838 patients with colorectal cancer using
comprehensive genomic and immune profiling (CGIP). The study
findings indicate that the machine-learning-driven approach
accurately assessed MSI status of colorectal cancer and endometrial
adenocarcinomas using CGIP data.
"Through our partnership with Illumina, we are deploying
innovative research opportunities that leverage the strengths of
our respective teams," said Shakti Ramkissoon, MD, PhD, vice
president, medical lead for oncology at Labcorp. "This algorithm is
especially exciting as a potential tool to improve assessment of
MSI status."
Greater evidence supporting CGP over SGT
Illumina continues to work with leading research institutions to
validate the clinical utility and value of CGP testing. CGP is a
single next-generation sequencing assay that assesses hundreds of
genes, including relevant cancer biomarkers, for therapy guidance.
This year, a real-world analysis done with SCRI will present data
demonstrating the performance of CGP versus SGT in
guideline-recommended biomarker selection in non-small-cell lung
cancer (NSCLC) (Abstract 8640).
"The findings showed that patients with stage IV NSCLC who
underwent SGT received results for all nine guideline-recommended
biomarkers only 1.2% of the time, as compared to 71.7% of the time
for patients tested with CGP testing," said Vivek Subbiah, MD, chief, Early-Phase Drug
Development at SCRI. "Our findings clearly indicate that relying
solely on single-gene testing or hot-spot testing leads to
incomplete biomarker testing, which can compromise targeted therapy
treatments for patients with NSCLC. To ensure optimal patient
outcomes, it is imperative that we transition to comprehensive
next-generation sequencing as the standard of care for NSCLC."
This work builds on evidence presented by Illumina and its
collaborators at ASCO 2023, including a study with Labcorp that
demonstrated that the initial use of SGT increases subsequent CGP
test cancellations, and concluded that SGT practice in the
community oncology setting does not meet practice guideline
recommendations and negatively impacts the potential benefit of
subsequent CGP for NSCLC patients (2023 Abstract 6506).
Data shows progress on MRD assay
At ASCO 2024, Illumina will present an analytical performance
evaluation of its MRD assay, highlighting its fast turnaround time,
low input requirements, and high sensitivity and specificity over
existing market options (Abstract 3060). Earlier this year,
Illumina announced collaborations with pharmaceutical companies to
innovate on its MRD research assay, which is currently under
development on a whole-genome backbone.
"We're committed to delivering impactful research to help enable
genomic testing in oncology care," said Pratheesh Sathyan, head of Oncology for the
Americas region at Illumina. "The work being presented at ASCO this
year, which includes research conducted with Eurofins, Labcorp, and
SCRI, will help advance access to precision oncology solutions for
patients."
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X,
Facebook, LinkedIn, Instagram, TikTok, and YouTube
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-drives-genomic-testing-as-standard-of-care-in-oncology-through-collaborative-research-presented-at-asco-302157733.html
SOURCE Illumina, Inc.